Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan

OBJECTIVE: Anaplastic lymphoma kinase (ALK) rearrangement is an important oncogenic driver in some non-small cell lung cancers (NSCLC). Treatment with ALK tyrosine kinase inhibitors improves survival. The availability of diagnostic immunohistochemistry (IHC) has led to a paradigm shift in ALK testin...

Descripción completa

Detalles Bibliográficos
Autores principales: Maraqa, Bayan, Al-Ashhab, Maxim, Sughayer, Maher A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Retrospective Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189535/
https://www.ncbi.nlm.nih.gov/pubmed/35689392
http://dx.doi.org/10.1177/03000605221104181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189535/
https://www.ncbi.nlm.nih.gov/pubmed/35689392
http://dx.doi.org/10.1177/03000605221104181

Ejemplares similares